Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease

Circulation: Heart Failure

Volumn 7, Issue 5, 2014, Pages 732-739

  Wannamethee, Goya S ^a   Welsh, Paul W ^b   Papacosta, Olia P ^a   Lennon, Lucy ^a   Whincup, Peter H ^c   Sattar, Naveed ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Heart failure; Parathyroid hormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; VITAMIN D;

AGED; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; KIDNEY DYSFUNCTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PRIORITY JOURNAL; VITAMIN D DEFICIENCY; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; HYPERPARATHYROIDISM; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; TIME; UNITED KINGDOM;

ADULT; AGED; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; GREAT BRITAIN; HEART FAILURE; HUMANS; HYPERPARATHYROIDISM; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARATHYROID HORMONE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84922993312     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001272     Document Type: Article

References (42)

1. Gandhi S, Myers RB. Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev. 2013;18:465-473.
2. Altay H, Colkesen Y. Parathyroid hormone and heart failure: novel biomarker strategy. Endocr Metab Immune Disord Drug Targets. 2013;13:100-104.
3. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-112.
4. Agarwal M, Phan A, Willix R Jr, Barber M, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther. 2011;16:354-363.
5. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
6. Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145-158.
7. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34-41.
8. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep. 2008;6:77-83.
9. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, Kinugawa T, Osaki S, Kato M, Tomikura Y, Igawa O, Hisatome I, Bilezikian JP, Shigemasa C. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722-4727. 10. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, Matsuoka K, Nakamura T, Koji T, Ito M. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395-398.
10. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, Matsuoka K, Nakamura T, Koji T, Ito M. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395'398.
11. Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26:1390-1394.
12. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003;24:2054-2060.
13. Rienstra M, Lubitz SA, Zhang ML, Cooper RR, Ellinor PT. Elevation of parathyroid hormone levels in atrial fibrillation. J Am Coll Cardiol. 2011;57:2542-2543.
14. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-1598.
15. van Ballegooijen AJ, Visser M, Kestenbaum B, Siscovick DS, de Boer IH, Gottdiener JS, deFilippi CR, Brouwer IA. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol. 2013;111:418-424.
16. van Ballegooijen AJ, Visser M, Cotch MF, Arai AE, Garcia M, Harris TB, Launer LJ, Eiríksdóttir G, Gudnason V, Brouwer IA. Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab. 2013;98:2544-2552.
17. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, Muhlestein JB. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162:331-339.e2.
18. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165:655-64, 664.e1.
19. Welsh P, Doolin O, McConnachie A, Boulton E, McNeil G, Macdonald H, Hardcastle A, Hart C, Upton M, Watt G, Sattar N. Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study. J Clin Endocrinol Metab. 2012;97:4578-4587.
20. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS, Siscovick DS. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58:1433-1441.
21. Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Arnlöv J. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186-1192.
22. di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, Isermann B, Hense HW, Dierkes J, Boeing H, Stangl GI, Weikert C. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014;99:947-955.
23. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappé DL, Muhlestein JB; Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106:963-968.
24. Thomas GN, ó Hartaigh B, Bosch JA, Pilz S, Loerbroks A, Kleber ME, Fischer JE, Grammer TB, Böhm BO, März W. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes Care. 2012;35:1158-1164.
25. Liu L, Chen M, Hankins SR, Nùñez AE, Watson RA, Weinstock PJ, Newschaffer CJ, Eisen HJ; Drexel Cardiovascular Health Collaborative Education, Research, and Evaluation Group. Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular disease, and premature mortality from all-cause in United States adults. Am J Cardiol. 2012;110:834-839.
26. Petrone AB, Weir NL, Steffen BT, Tsai MY, Gaziano JM, Djoussé L. Plasma vitamin D-binding protein and risk of heart failure in male physicians. Am J Cardiol. 2013;112:827-830.
27. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. Br Med J (Clin Res Ed). 1981;283:179-186.
28. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol. 2011;58:1870-1877.
29. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-1790.
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
31. Wannamethee SG, Welsh P, Whincup PH, Lennon L, Papacosta O, Sattar N. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study. Eur J Heart Fail. 2014;16:25-32.
32. Knox S, Harris J, Calton L, Wallace AM. A simple automated solidphase extraction procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2009;46(Pt 3):226-230.
33. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:340-350.
34. Walker M, Shaper AG, Lennon L, Whincup PH. Twenty year follow-up of a cohort based in general practices in 24 British towns. J Public Health Med. 2000;22:479-485.
35. Task FM, McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK,Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with t the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
36. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52:1949-1956.
37. Bosworth C, Sachs MC, Duprez D, Hoofnagle AN, Ix JH, Jacobs DR Jr, Peralta CA, Siscovick DS, Kestenbaum B, de Boer IH. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxf). 2013;79:429-436.
38. Altay H, Zorlu A, Bilgi M, Erol T, Yilmaz MB. Usefulness of parathyroid hormone as a predictor of heart failure with preserved ejection fraction. Biomarkers. 2012;17:447-454.
39. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11(5 suppl):S81-S83.
40. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34-41.
41. Kaila K, Haykowsky MJ, Thompson RB, Paterson DI. Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Fail Rev. 2012;17:555-562.
42. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77:93-100.